Publications by authors named "L Abecia"
Phloroglucinol is a key byproduct of gut microbial metabolism that has been widely used as a treatment for irritable bowel syndrome. Here, we demonstrate that phloroglucinol tempers macrophage responses to pro-inflammatory pathogens and stimuli. , phloroglucinol administration decreases gut and extraintestinal inflammation in murine models of inflammatory bowel disease and systemic infection.
View Article and Find Full Text PDFThe initial exposure to pathogens and commensals confers innate immune cells the capacity to respond distinctively upon a second stimulus. This training capacity might play key functions in developing an adequate innate immune response to the continuous exposure to bacteria. However, the mechanisms involved in induction of trained immunity by commensals remain mostly unexplored.
View Article and Find Full Text PDFArticle Synopsis
- * Research shows that the absence of a protein called MCJ in macrophages leads to changes in gut microbiota, which may be key to understanding why some patients are anti-TNF refractory.
- * The study highlights the importance of macrophage mitochondrial function in the gut, suggesting that microbial changes can influence inflammation severity and treatment effectiveness.
Article Synopsis
- * Mice lacking the mitochondrial protein MCJ show increased sensitivity to colitis, but this study reveals that their altered gut microbiota can pass on this susceptibility to germ-free mice through fecal microbiota transplantation (FMT).
- * The research identifies specific microbiota and immune responses, like increased IgA coating on bacteria in MCJ-deficient mice, which may contribute to the progression of IBD, highlighting the potential for microbial biomarkers in predicting ulcerative colitis patient outcomes.
Objective: Primary non-response and secondary loss of response to anti-TNF agents are common in inflammatory bowel disease. Increasing drug concentrations are correlated to better clinical response and remission rates. Combination of granulocyte-monocyte apheresis (GMA) with anti-tumor necrosis factor (TNF) agents could be an option in these patients.
View Article and Find Full Text PDF